CMS Proposes Major TAVR Changes, Including Medicare Coverage for Asymptomatic Patients

Why It Matters

Broadening Medicare coverage could dramatically increase TAVR utilization among previously untreated patients, improving outcomes while the retained safeguards aim to preserve procedural safety and quality.

Key Takeaways

• CMS proposes Medicare coverage for asymptomatic severe aortic stenosis patients
• Heart team surgeon participation remains mandatory under new draft policy
• Operator volume thresholds and CED requirements retained to ensure safety
• Edwards' early TAVR data and FDA approval drive policy shift
• Public comments accepted until July 15, influencing final decision

Pulse Analysis

The transcatheter aortic valve replacement (TAVR) has moved from a niche solution for high‑risk patients to a mainstream therapy for severe aortic stenosis across risk categories. Recent randomized trials, notably the EARLY TAVR study published in the New England Journal of Medicine, demonstrated that intervening in asymptomatic patients reduces heart‑failure events and improves survival. Coupled with the FDA’s May clearance of Edwards’ Sapien 3, Sapien 3 Ultra and Ultra Resilia systems for this indication, the clinical evidence now supports broader adoption. Medicare’s coverage decision therefore becomes a pivotal lever for scaling the technology.

CMS’s draft National Coverage Determination (NCD) proposes to extend Medicare reimbursement to asymptomatic severe AS, a move that could add millions of eligible beneficiaries to the TAVR pipeline. For device manufacturers, the policy translates into a sizable revenue boost; Edwards, which championed the proposal, stands to capture a larger share of the growing market, while competitors such as Medtronic anticipate similar gains. By preserving surgeon participation, procedural volume minimums, and coverage‑with‑evidence‑development (CED) requirements, CMS aims to balance rapid access with the safeguards that have underpinned the specialty’s safety record.

The final NCD will hinge on feedback collected through the July 15 public comment window. Stakeholders are likely to argue for maintaining rigorous heart‑team protocols and robust registry reporting to monitor outcomes as the patient pool expands. Analysts predict that once finalized, the policy could accelerate the shift toward earlier intervention, prompting hospitals to invest in dedicated TAVR programs and potentially reshaping referral patterns. Ultimately, the decision will test how effectively regulators can align emerging clinical data with reimbursement structures while protecting quality of care.